News|Articles|November 19, 2026

Q&A: Interpreting Pediatric Nemolizumab Data for AD, With Lawrence Eichenfield, MD

Fact checked by: Tim Smith
Listen
0:00 / 0:00

Key Takeaways

  • Caregiver-reported worst itch–scratch assessments provide more valid pruritus measurement than child self-report in the youngest patients, enabling consistent tracking across ages 2 to 11 years.
  • Monthly nemolizumab injections with concomitant topical corticosteroids yielded early 40% to 60% itch reductions, stabilizing by ~8 weeks and sustained through 1 year.
SHOW MORE

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

Children younger than 12 years with moderate to severe atopic dermatitis have few systemic options, and the IL-31 receptor alpha antagonist nemolizumab is approved only for patients 12 years and older.² At the Pediatric Dermatology Research Alliance (PeDRA) 2026 Annual Conference, Galderma presented open-label phase 2 results for weight-tiered nemolizumab plus topical therapy over 52 weeks in 3 age- and weight-based cohorts of children aged 2 to 11 years.¹ Across cohorts, 56% to 72% of participants achieved an itch improvement of 4 points or more on the Peak Pruritus Numerical Rating Scale at week 16. Sleep disturbance scores fell 70% to 78%, and Galderma reported no new safety signals.¹

Lawrence Eichenfield, MD, known for his roles as professor of dermatology and pediatrics at the University of California San Diego School of Medicine and chief of pediatric dermatology at Rady Children’s Hospital-San Diego, led the research. In this interview, he explains how caregiver-reported measures capture itch in the youngest patients, why sleep should come up at every visit, and the limitations clinicians should weigh before the data reach practice:

HCPLive: How should clinicians interpret the itch results in children aged 2 to 11, and what signs of improvement should they look for in practice?

Lawrence Eichenfield, MD: The nemolizumab study was a broad age range. It was 2 to 11 years of age, and these are ages where it’s a little different. You can certainly ask a 10-year-old for their itch scores, 0 to 10, etc. You can ask a 2-year-old, but don’t expect a response that means anything. A 0-to-10 worst itch in the last 24 hours isn’t going to mean anything to a 2-year-old. But we do have surrogate measures which have been shown in studies to be highly reliable. So where we might use a 0-to-10 itch score with a worst itch score over 24 hours, we have a worst itch-scratch score, which is a surrogate marker from parents or other caretakers to mark how the itch was.

I think the data was pretty consistent. There were essentially 3 cohorts, but there were 2 cohorts we really looked at in detail in this study, which divided the kids by age: 2- to 6-year-olds and then 7- to 11-year-olds. The itch data was really remarkably good, and there was a lot of consistency in terms of a decrease in itch. The 4-point improvement score, PP-NRS as we say, was 56% to 72% in the different cohorts, so it showed a nice itch response and also a consistent itch response over time. This was structured with shots every month, finished at 16 weeks, and then enrolled into a continuation part of the study over 52 weeks. During the study, all patients got topical corticosteroids as well.

But the punchline is the itch response was very good, with an impressive drop in itch during the clinical study. In terms of the change in the numbers, very rapidly you get a 40% to 60% decrease in itch, and then the average pruritus scores really stayed low during the course of the study. They were mostly pretty stable from almost 8 weeks, even before the 16-week time course, through the 1-year course of the study in the different cohorts.

HCPLive: How does poor sleep affect these children and their families, and should dermatologists ask about sleep at every visit?

Lawrence Eichenfield, MD: I do. I really do think it’s core. I always try to tell families we try to get to the point of minimal rash, minimal itch, and minimal sleep disturbance. The sleep disturbance obviously is highly impacted by itch and the state of the cutaneous eczema. But it’s also something I think has compounding effects, because if kids are up, often other family members are up. The mothers are often up. It disrupts the household, and then you can also have a less well-rested child the next day, whether it be a toddler or an 11-year-old. That makes life harder. It makes performance in school harder in school-aged kids. It creates crankier kids in preschools.

So the sleep disturbance scores are really quite important. There’s a 70% to 78% drop in sleep disturbance in this study, maintained over the 52-week course of the study, and other data points we’ve looked at have shown earlier response with that as well. So I think sleep disturbance is a really good endpoint to go for, to try to minimize the compound impact uncontrolled eczema otherwise has.

HCPLive: What do the quality-of-life improvements look like in a child’s daily life, and are these tools practical to use in clinic?

Lawrence Eichenfield, MD: First of all, they’re not necessarily practical to use in clinic. As much as I’m into eczema and the multidimensional part of eczema and its impact on family, which I really am and ask about all the time, I don’t do the Children’s Dermatology Life Quality Index or the infant version of that, the Infants’ Dermatitis Quality of Life Index, in clinical practice. We sometimes do those as part of clinical studies, but those are really composites based on different domains of the impact of eczema on the life of the individual. I really look at them to get a sense of the influence of a drug.

Actually, the baseline scores were pretty impressive. About three-quarters of the patients were moderate, and 25% of the patients were severe, but the average children’s or infant dermatology quality of life index was 15 to 20, which means the disease is very much affecting the individuals. They had very nice data showing clinically meaningful improvements, with a drop of about 10 points from the baseline of 15 to 20 in the children’s quality of life.

So I do like that data set, because when the disease calms down, both itch and rash and sleep disturbance, it really shows robust changes. Decreasing the negative impact uncontrolled eczema has on the individual, I think, is really important. These measures are important to really give us a sense of how well the drug is working, not just on different isolated aspects of it, but really on the domains which comprise the otherwise amplification effect of uncontrolled eczema.

HCPLive: What do clinicians still need to learn about nemolizumab in young children, and where should future research focus?

Lawrence Eichenfield, MD: The number of patients in the studies was in the 30s in each of the cohorts. They all used topical corticosteroids, which were standard and appropriate. They were open-label studies. That’s a limitation of the study when you look at the results: there’s no comparison group, so it’s easy to be very positive about how the patients are doing.

But I do think these studies really support the projection of a time when nemolizumab is approved not just for 12 years of age or older, but for younger patients as well with moderate to severe atopic dermatitis, and this is the next step. They already had their pharmacokinetic data showing appropriate matching. The safety data looked quite good as well. Essentially, there was nothing different than what we’ve seen in the adolescent and adult trials previously, and no significant adverse events in this protocol.

So we have the potential benefits, and this will set us up. Right now, we haven’t moved toward approval yet under 12, but this is a big step toward that. I think it’ll be very intriguing as we move forward to consider alternative systemic medications under age 12 for atopic dermatitis, and certainly remember this IL-31 blocker is really unique in terms of what it’s targeting from an anti-inflammatory, anti-itch standpoint.

Editor’s Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

References

  1. Galderma. PeDRA 2026: nemolizumab phase II data show long-term symptom relief for children aged 2 to 11 years with moderate-to-severe atopic dermatitis. Published October 15, 2026. Accessed November 19, 2026. https://www.galderma.com/news/pedra-2026-nemolizumab-phase-ii-data.
  2. HCPLive. Can nemolizumab help children under 12 with moderate-to-severe eczema? https://www.hcplive.com/view/can-nemolizumab-help-children-under-12-moderate-severe-eczema-. Published October 18, 2026. Accessed November 19, 2026.

Related to this article